{"component": "clause", "props": {"groups": [{"samples": [{"hash": "eMAvLkzxc60", "uri": "/contracts/eMAvLkzxc60#development-collaboration", "label": "Software License Agreement (Open Solutions Inc)", "score": 18.0, "published": true}, {"hash": "eKo9uYbwCW9", "uri": "/contracts/eKo9uYbwCW9#development-collaboration", "label": "Software License Agreement (Open Solutions Inc)", "score": 18.0, "published": true}, {"hash": "8S3LnFGToRz", "uri": "/contracts/8S3LnFGToRz#development-collaboration", "label": "Software License Agreement (Open Solutions Inc)", "score": 18.0, "published": true}], "snippet": "Appropriate representatives of OSI and BISYS shall meet at least semi-annually to discuss and review each other's product development plans and for OSI and BISYS to provide input based on competitive feature and function requirements. At any time during the Term or any Renewal Term of this Agreement, BISYS shall have the right to request certain development efforts related to the System and to Ancillary Products. To the extent it is mutually agreed that such development efforts enhance the overall value, marketability or competitive position of the System and the Ancillary Products, such efforts shall be funded by OSI. BISYS shall be given the opportunity to contribute to such efforts either through funding and/or contribution of application specifications and/or certain technology to expedite delivery or to address certain customer requirements that may not be considered to significantly enhance the overall value, marketability or competitive value of the System and the Ancillary Products. OSI reserves all right, in its sole discretion, to determine the scope and nature of any and all development activities that will be performed to the System and Ancillary Products regardless of the source of funding.", "snippet_links": [{"key": "representatives-of", "type": "clause", "offset": [12, 30]}, {"key": "to-discuss", "type": "definition", "offset": [79, 89]}, {"key": "and-review", "type": "clause", "offset": [90, 100]}, {"key": "plans-and", "type": "definition", "offset": [134, 143]}, {"key": "to-provide", "type": "definition", "offset": [162, 172]}, {"key": "based-on", "type": "clause", "offset": [179, 187]}, {"key": "at-any-time", "type": "clause", "offset": [235, 246]}, {"key": "during-the-term", "type": "clause", "offset": [247, 262]}, {"key": "term-of-this-agreement", "type": "clause", "offset": [278, 300]}, {"key": "right-to-request", "type": "clause", "offset": [323, 339]}, {"key": "development-efforts", "type": "clause", "offset": [348, 367]}, {"key": "related-to", "type": "clause", "offset": [368, 378]}, {"key": "the-system", "type": "definition", "offset": [379, 389]}, {"key": "ancillary-products", "type": "clause", "offset": [397, 415]}, {"key": "to-the-extent", "type": "clause", "offset": [417, 430]}, {"key": "it-is-mutually-agreed-that", "type": "clause", "offset": [431, 457]}, {"key": "competitive-position", "type": "clause", "offset": [527, 547]}, {"key": "by-osi", "type": "clause", "offset": [619, 625]}, {"key": "the-opportunity", "type": "clause", "offset": [648, 663]}, {"key": "contribution-of", "type": "clause", "offset": [724, 739]}, {"key": "customer-requirements", "type": "definition", "offset": [836, 857]}, {"key": "sole-discretion", "type": "clause", "offset": [1037, 1052]}, {"key": "nature-of", "type": "clause", "offset": [1081, 1090]}, {"key": "development-activities", "type": "clause", "offset": [1103, 1125]}, {"key": "source-of-funding", "type": "definition", "offset": [1204, 1221]}], "size": 3, "hash": "aba0913acc550ccf2d120d471253079f", "id": 1}, {"samples": [{"hash": "i1SmgPF4hGA", "uri": "/contracts/i1SmgPF4hGA#development-collaboration", "label": "Research and Development (Sandisk Corp)", "score": 18.0, "published": true}], "snippet": "2.1 SanDisk will send, and Toshiba will receive, such number of Assignees as are mutually agreed upon, at AMC or other Toshiba facilities during the term of this Agreement in order for SanDisk to participate in the development work of the Contract Technology as set forth in Exhibit B (the \"Development Work\"), which may be modified by Toshiba and SanDisk from time to time, and in accordance with the direction of Toshiba; PROVIDED THAT such modification to the Development Work shall not materially affect SanDisk's permitted access to the Contract Technology. For avoidance of doubt, it is agreed by the parties that SanDisk shall not have any right to have access to, and its Assignees shall not have access to, any technical information or data which are not relevant or necessary to perform the Development Work or any technical information or data for which access by Assignees is prohibited by any binding contract of Toshiba and any third party, and that no right or license is granted to SanDisk with respect to said technical information or data. The project managers of SanDisk and Toshiba shall periodically discuss, determine and monitor the details of the Development Work; PROVIDED THAT in case of any dispute between the respective project managers, the manager of Toshiba may determine such details, taking into consideration the reasonable input made by SanDisk. In order to perform the Development Work, Toshiba shall provide the Assignees with sufficient office equipment, including personal computers and telephones.\n2.2 SanDisk shall ensure that its Assignees shall comply with the safety, security and all other applicable practices, regulations of Toshiba and specific instructions or directions to be made by Toshiba while such Assignees are in Toshiba's facilities. SanDisk agrees to be responsible for all salaries, benefits, expense reimbursements and other payments to its Assignees and workers insurance for Assignees and shall indemnify and hold Toshiba harmless from any claims against Toshiba arising out of any injury to any Assignee.\n2.3 SanDisk shall be responsible for the living, traveling and all other out-of-pocket expenses for its Assignees.", "snippet_links": [{"key": "number-of", "type": "clause", "offset": [54, 63]}, {"key": "mutually-agreed", "type": "clause", "offset": [81, 96]}, {"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [138, 171]}, {"key": "participate-in", "type": "definition", "offset": [196, 210]}, {"key": "contract-technology", "type": "clause", "offset": [239, 258]}, {"key": "exhibit-b", "type": "definition", "offset": [275, 284]}, {"key": "from-time-to-time", "type": "clause", "offset": [356, 373]}, {"key": "in-accordance-with", "type": "definition", "offset": [379, 397]}, {"key": "provided-that", "type": "clause", "offset": [424, 437]}, {"key": "modification-to", "type": "clause", "offset": [443, 458]}, {"key": "access-to-the", "type": "clause", "offset": [528, 541]}, {"key": "for-avoidance-of-doubt", "type": "clause", "offset": [563, 585]}, {"key": "by-the-parties", "type": "clause", "offset": [600, 614]}, {"key": "right-to-have", "type": "clause", "offset": [647, 660]}, {"key": "technical-information", "type": "definition", "offset": [720, 741]}, {"key": "binding-contract", "type": "clause", "offset": [906, 922]}, {"key": "third-party", "type": "clause", "offset": [942, 953]}, {"key": "no-right-or-license", "type": "clause", "offset": [964, 983]}, {"key": "granted-to", "type": "definition", "offset": [987, 997]}, {"key": "with-respect-to", "type": "clause", "offset": [1006, 1021]}, {"key": "project-managers", "type": "definition", "offset": [1062, 1078]}, {"key": "details-of-the", "type": "clause", "offset": [1156, 1170]}, {"key": "in-case-of", "type": "clause", "offset": [1203, 1213]}, {"key": "the-manager", "type": "definition", "offset": [1267, 1278]}, {"key": "taking-into-consideration", "type": "clause", "offset": [1318, 1343]}, {"key": "in-order-to", "type": "clause", "offset": [1382, 1393]}, {"key": "provide-the", "type": "clause", "offset": [1438, 1449]}, {"key": "office-equipment", "type": "clause", "offset": [1476, 1492]}, {"key": "computers-and-telephones", "type": "clause", "offset": [1513, 1537]}, {"key": "the-safety", "type": "clause", "offset": [1601, 1611]}, {"key": "security-and", "type": "clause", "offset": [1613, 1625]}, {"key": "other-applicable", "type": "clause", "offset": [1630, 1646]}, {"key": "specific-instructions", "type": "clause", "offset": [1685, 1706]}, {"key": "agrees-to", "type": "clause", "offset": [1801, 1810]}, {"key": "responsible-for", "type": "clause", "offset": [1814, 1829]}, {"key": "expense-reimbursements", "type": "definition", "offset": [1854, 1876]}, {"key": "payments-to", "type": "definition", "offset": [1887, 1898]}, {"key": "insurance-for", "type": "clause", "offset": [1925, 1938]}, {"key": "indemnify-and-hold", "type": "clause", "offset": [1959, 1977]}, {"key": "arising-out-of", "type": "definition", "offset": [2027, 2041]}, {"key": "pocket-expenses", "type": "definition", "offset": [2150, 2165]}], "size": 3, "hash": "60ce02a5e035e422cec49ab225891bfd", "id": 2}, {"samples": [{"hash": "fftvj7F9aqz", "uri": "/contracts/fftvj7F9aqz#development-collaboration", "label": "License and Collaboration Agreement (Cytokinetics Inc)", "score": 32.189596167, "published": true}, {"hash": "4TyLWLCDy7L", "uri": "/contracts/4TyLWLCDy7L#development-collaboration", "label": "License and Collaboration Agreement (Cytokinetics Inc)", "score": 31.8473648186, "published": true}], "snippet": "(a) Cytokinetics shall keep the JDC reasonably informed on its plans (including any updates and amendment thereto) for the global Development of the Product in sufficient detail for Ji Xing to conform the Development of the Product in the Field in the Territory to the Global Development Plan (the \u201cGlobal Development Plan\u201d). Except as expressly agreed [*].\n(b) The Parties shall collaborate with respect to the Development of the Product across their territories, and may agree to collaborate in the conduct of Clinical Trials designed to obtain and maintain Regulatory Approval of the Product in multiple countries and jurisdictions, both in and outside the Territory, through the conduct of Clinical Trials in multiple sites in such countries and jurisdictions as part of one unified Clinical Trial or separately but concurrently in accordance with a common Clinical Trial protocol (such Clinical Trial, a \u201cMulti-Region Trial\u201d). [*].\n(c) [*].\n(d) [*].", "snippet_links": [{"key": "the-jdc", "type": "clause", "offset": [28, 35]}, {"key": "and-amendment", "type": "clause", "offset": [92, 105]}, {"key": "the-global", "type": "definition", "offset": [119, 129]}, {"key": "development-of-the-product", "type": "clause", "offset": [130, 156]}, {"key": "sufficient-detail", "type": "clause", "offset": [160, 177]}, {"key": "the-development", "type": "clause", "offset": [201, 216]}, {"key": "in-the-field", "type": "clause", "offset": [232, 244]}, {"key": "in-the-territory", "type": "clause", "offset": [245, 261]}, {"key": "global-development-plan", "type": "definition", "offset": [269, 292]}, {"key": "the-parties-shall", "type": "clause", "offset": [362, 379]}, {"key": "with-respect-to", "type": "clause", "offset": [392, 407]}, {"key": "agree-to", "type": "clause", "offset": [473, 481]}, {"key": "conduct-of-clinical-trials", "type": "clause", "offset": [501, 527]}, {"key": "approval-of-the-product", "type": "clause", "offset": [571, 594]}, {"key": "outside-the-territory", "type": "clause", "offset": [648, 669]}, {"key": "multiple-sites", "type": "clause", "offset": [713, 727]}, {"key": "in-accordance-with", "type": "definition", "offset": [833, 851]}, {"key": "clinical-trial-protocol", "type": "clause", "offset": [861, 884]}], "size": 2, "hash": "d37882e7729654abecaae4616c194403", "id": 3}, {"samples": [{"hash": "gS5T7keWmHc", "uri": "/contracts/gS5T7keWmHc#development-collaboration", "label": "License and Collaboration Agreement (Zealand Pharma a/S)", "score": 28.5099247091, "published": true}, {"hash": "6Z9oI484NlC", "uri": "/contracts/6Z9oI484NlC#development-collaboration", "label": "License and Collaboration Agreement (Zealand Pharma a/S)", "score": 27.4558521561, "published": true}], "snippet": "Zealand Pharma and BI will collaborate to advance the preclinical and clinical Development of the Collaboration Compounds.", "snippet_links": [{"key": "to-advance", "type": "definition", "offset": [39, 49]}, {"key": "collaboration-compounds", "type": "clause", "offset": [98, 121]}], "size": 2, "hash": "16789076ff8d3e40c511e6eb18e1fdc0", "id": 4}, {"samples": [{"hash": "9Wp6fjUOADY", "uri": "/contracts/9Wp6fjUOADY#development-collaboration", "label": "Mobile Wimax Network Collaboration Agreement (Clearwire Corp)", "score": 18.0, "published": true}, {"hash": "38qXb56B2qz", "uri": "/contracts/38qXb56B2qz#development-collaboration", "label": "Mobile Wimax Network Collaboration Agreement (Clearwire Corp)", "score": 18.0, "published": true}], "snippet": "2.1 [***] Clearwire and Intel will work together to determine the [***]. Clearwire will develop or have developed a [***]. If Clearwire decides to develop a [***] Clearwire and Intel will work together, and will use commercially reasonable efforts to obtain NextNet's participation, to develop [***]", "snippet_links": [{"key": "will-work", "type": "clause", "offset": [30, 39]}, {"key": "determine-the", "type": "clause", "offset": [52, 65]}, {"key": "to-develop", "type": "definition", "offset": [144, 154]}, {"key": "efforts-to-obtain", "type": "clause", "offset": [240, 257]}], "size": 2, "hash": "01c8f51765f15c9a07fd677158d64907", "id": 5}, {"samples": [{"hash": "9YtSLYdsZ9n", "uri": "/contracts/9YtSLYdsZ9n#development-collaboration", "label": "Development, Licensing and Distribution Agreement (Resound Corp)", "score": 18.0, "published": true}, {"hash": "9Mw4VKfFTIn", "uri": "/contracts/9Mw4VKfFTIn#development-collaboration", "label": "Development, Licensing and Distribution Agreement (Resound Corp)", "score": 18.0, "published": true}], "snippet": "Danavox, ReSound and AL2 hereby agree to jointly undertake the Development Program. The parties contemplate that the Development Program will be carried out pursuant to this Agreement over a four-year period (the \"Term\"), unless the Term is extended by agreement of each of Danavox and ReSound.", "snippet_links": [{"key": "agree-to", "type": "clause", "offset": [32, 40]}, {"key": "the-development-program", "type": "clause", "offset": [59, 82]}, {"key": "the-parties", "type": "definition", "offset": [84, 95]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [157, 183]}, {"key": "year-period", "type": "definition", "offset": [196, 207]}, {"key": "the-term", "type": "clause", "offset": [229, 237]}, {"key": "by-agreement", "type": "definition", "offset": [250, 262]}], "size": 2, "hash": "555416a547fc0da2ebba7560cad6e589", "id": 6}, {"samples": [{"hash": "9N5mumzy6mg", "uri": "/contracts/9N5mumzy6mg#development-collaboration", "label": "License and Research Collaboration Agreement (Geron Corporation)", "score": 16.0, "published": true}, {"hash": "2TgYrSXWoQM", "uri": "/contracts/2TgYrSXWoQM#development-collaboration", "label": "License and Research Collaboration Agreement (Geron Corporation)", "score": 16.0, "published": true}], "snippet": "Section 4.5 of the KH Agreement is hereby amended to grant P&U the right to conduct the United States clinical trials and to collect the United States clinical data in place of Geron. Section 4.6 of the KH Agreement is hereby rendered null and void.", "snippet_links": [{"key": "section-45", "type": "clause", "offset": [0, 11]}, {"key": "right-to-conduct", "type": "clause", "offset": [67, 83]}, {"key": "the-united-states", "type": "definition", "offset": [84, 101]}, {"key": "clinical-trials", "type": "definition", "offset": [102, 117]}, {"key": "clinical-data", "type": "definition", "offset": [151, 164]}, {"key": "place-of", "type": "clause", "offset": [168, 176]}, {"key": "section-46", "type": "clause", "offset": [184, 195]}, {"key": "null-and-void", "type": "definition", "offset": [235, 248]}], "size": 2, "hash": "4ff838e0a21a5b48d93132c6535752f5", "id": 7}, {"samples": [{"hash": "4vmEIrI1ZdC", "uri": "/contracts/4vmEIrI1ZdC#development-collaboration", "label": "License, Development and Marketing Agreement (Netiq Corp)", "score": 18.0, "published": true}], "snippet": "a. NetIQ shall deliver to Microsoft the Licensed Software and an initial version of the Licensed Materials within two (2) weeks of the Effective Date. Upon receipt of such Licensed Software and Licensed Materials, Microsoft shall evaluate such Licensed Software and Licensed Materials. Microsoft shall communicate to NetIQ its acceptance or rejection of the Licensed Software and Licensed Materials within thirty (30) days of the Effective Date. Microsoft's acceptance shall not be deemed a waiver by Microsoft of NetIQ's obligation to deliver the Licensed Software and Licensed Materials hereunder. NetIQ shall deliver the final version of the Licensed Materials within four (4) weeks of the Effective Date. Upon commercial release of OM version 3.3 by NetIQ, Microsoft, upon reasonable notice, shall have the right to audit the source code tree for OM version 3.3 during normal business hours. Such audit shall be at Microsoft's expense. NetIQ agrees to provide all reasonably necessary assistance to Microsoft to facilitate such audit. NetIQ agrees that there will be no material functional regression of the commercially released OM version 3.3, as compared with OM version 3.3 existing as of the Effective Date.\nb. During the Collaboration Period, except as limited herein and by Section 5(a), NetIQ shall provide the Development Team, which, at Microsoft's election, shall be comprised of a minimum of up to **** Team Members at the Microsoft Facility and which shall consist of at least **** engineers at all times. Ten days after the Release To Manufacturing of OM version 3.3, NetIQ shall use commercially reasonable efforts to provide, upon thirty (30) days prior notice from Microsoft, a maximum, at any one time, of up to **** Team Members. During the first six months of the Collaboration Period, at least one (1) Team Member at the Microsoft Facility shall be a build/development engineer and such build/development engineer shall be on-site at the Microsoft Facility within one month of the Effective Date. The remaining **** Team Members designated for the Microsoft Facility shall be on-site at the Microsoft Facility within two months of the Effective Date. The Team Members not designated for the Microsoft Facility shall be at NetIQ's Facility. NetIQ acknowledges that, with regard to the Development Team, such Development Team shall be fully dedicated to the Microsoft work. Microsoft shall pay **** per month to NetIQ for each Team Member, invoiced quarterly and payable within 30 days. NetIQ agrees to provide up to **** person-years of Development Team resources to Microsoft. All work done by the Team Members shall be on a work-for-hire basis, and Microsoft shall own all right, title and interest to such **** [C]onfidential treatment has been requested for the redacted portions. The confidential redacted portions have been filed separately with the Securities and Exchange Commission. 4\nwork. When used herein, the terms Facility, Microsoft Facility and NetIQ Facility shall include reasonable access to office space, telephones, computers, and office supplies at the host Party's expense, but such expenses shall not include travel, room or board.\nc. At Microsoft's election, NetIQ and Microsoft will collaborate on the definition of a licensing mechanism that provides a coherent licensing strategy to customers of MOM and MOM Extending Technology.\nd. Team Members shall be highly familiar with and highly experienced with the Microsoft Windows platform and the development of OM. NetIQ shall use commercially reasonable efforts to ensure that (i) each Team Member meets Microsoft's reasonable hiring standards, as communicated to NetIQ, and (ii) all NetIQ personnel comply with Microsoft's published standard policies and procedures with respect to on-site personnel at the Microsoft Facility. Such standard policies and procedures shall not alter the intellectual property rights between the Parties set forth in this Agreement.\ne. At NetIQ's expense, NetIQ may also maintain up to **** NetIQ Employees as technical contacts at the Microsoft Facility during the Collaboration Period, to aid in NetIQ's development of MOM Extending Technologies. Such **** Employees shall not be considered as a part of the Development Team resources that NetIQ is obligated to provide pursuant to Section 4(b). At Microsoft's expense, Microsoft may also maintain up to **** Microsoft employees as technical contacts at a NetIQ Facility during the Collaboration Period, to assist with Microsoft's development obligations.\nf. Unless mutually agreed upon differently by the Parties (at the Vice- President level for each Party), NetIQ shall use commercially reasonable efforts to deliver working, demonstrable betas of Agents for any three of the following four platforms: (i) AIX, (ii) HP-UX, (iii) Solaris and (iv) Novell server software. NetIQ will also use commercially reasonable efforts to deliver working, demonstrable betas of modules for any two of the following three applications: (i) Lotus Domino, (ii) Oracle 8i Enterprise Edition, and (iii) SAP R/3. NetIQ shall use commercially reasonable efforts to complete all such beta Agents or modules in time for the first official announcement of the Release To Manufacturing version (the \"Launch\") of MOM. With respect to the remaining beta Agents and modules for the fourth platform and third application not anticipated to be completed by the Launch, NetIQ shall use commercially reasonable efforts to complete such Agents and modules within four months of the Launch. NetIQ shall use commercially reasonable efforts to complete final versions of all such Agents and modules no later than six months after Launch.\ng. NetIQ may, from time to time, engage Microsoft in discussions regarding providing additional items as part of the Licensed Software and/or Licensed Materials. Should NetIQ provide such additional items to Microsoft, the parties shall engage in good faith negotiations regarding when Microsoft may incorporate such items in a future release of MOM. The ultimate decision whether to include such technologies shall reside with Microsoft.\nh. Upon NetIQ's request, Microsoft shall use commercially reasonable efforts to provide information to NetIQ on publicly documented application programming interfaces and database schema (\"APIs\") for MOM. NetIQ shall only write to APIs. Should NetIQ require a particular new API, NetIQ shall notify Microsoft in writing, and Microsoft shall in good faith discuss the requirements of such API with NetIQ. Notwithstanding any provision to the contrary, Microsoft retains sole discretion to document, expose, or otherwise make available to any Party, including NetIQ, any APIs. **** [C]onfidential treatment has been requested for the redacted portions. The confidential redacted portions have been filed separately with the Securities and Exchange Commission.\ni. For avoidance of doubt, NetIQ may build MOM Agent Subsystems for Win9x, NT Embedded (based on Windows NT 4.0), WinCE, Windows ME, and future Microsoft operating systems, whether on PCs or non-PC devices.", "snippet_links": [{"key": "to-microsoft", "type": "clause", "offset": [23, 35]}, {"key": "the-licensed-software", "type": "clause", "offset": [36, 57]}, {"key": "the-licensed-materials", "type": "clause", "offset": [84, 106]}, {"key": "upon-receipt-of", "type": "definition", "offset": [151, 166]}, {"key": "acceptance-or-rejection", "type": "clause", "offset": [327, 350]}, {"key": "within-thirty", "type": "clause", "offset": [399, 412]}, {"key": "by-microsoft", "type": "clause", "offset": [498, 510]}, {"key": "obligation-to-deliver", "type": "clause", "offset": [522, 543]}, {"key": "final-version", "type": "clause", "offset": [624, 637]}, {"key": "release-of", "type": "clause", "offset": [725, 735]}, {"key": "upon-reasonable-notice", "type": "clause", "offset": [772, 794]}, {"key": "right-to-audit", "type": "clause", "offset": [811, 825]}, {"key": "source-code", "type": "definition", "offset": [830, 841]}, {"key": "normal-business-hours", "type": "definition", "offset": [873, 894]}, {"key": "to-provide", "type": "definition", "offset": [953, 963]}, {"key": "reasonably-necessary", "type": "clause", "offset": [968, 988]}, {"key": "assistance-to", "type": "clause", "offset": [989, 1002]}, {"key": "no-material", "type": "clause", "offset": [1071, 1082]}, {"key": "commercially-released", "type": "definition", "offset": [1112, 1133]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [1191, 1215]}, {"key": "collaboration-period", "type": "clause", "offset": [1231, 1251]}, {"key": "development-team", "type": "clause", "offset": [1323, 1339]}, {"key": "comprised-of", "type": "clause", "offset": [1382, 1394]}, {"key": "team-members", "type": "definition", "offset": [1419, 1431]}, {"key": "consist-of", "type": "clause", "offset": [1474, 1484]}, {"key": "at-all-times", "type": "definition", "offset": [1509, 1521]}, {"key": "days-after", "type": "definition", "offset": [1527, 1537]}, {"key": "the-release", "type": "clause", "offset": [1538, 1549]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [1598, 1633]}, {"key": "upon-thirty", "type": "clause", "offset": [1646, 1657]}, {"key": "prior-notice", "type": "clause", "offset": [1668, 1680]}, {"key": "first-six-months", "type": "clause", "offset": [1764, 1780]}, {"key": "facility-shall", "type": "clause", "offset": [1856, 1870]}, {"key": "development-engineer", "type": "definition", "offset": [1882, 1902]}, {"key": "one-month", "type": "definition", "offset": [1989, 1998]}, {"key": "the-team", "type": "definition", "offset": [2176, 2184]}, {"key": "with-regard-to", "type": "clause", "offset": [2290, 2304]}, {"key": "per-month", "type": "clause", "offset": [2422, 2431]}, {"key": "payable-within", "type": "definition", "offset": [2486, 2500]}, {"key": "all-work", "type": "clause", "offset": [2602, 2610]}, {"key": "title-and-interest", "type": "clause", "offset": [2706, 2724]}, {"key": "filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [2854, 2914]}, {"key": "the-terms", "type": "definition", "offset": [2942, 2951]}, {"key": "office-space", "type": "definition", "offset": [3035, 3047]}, {"key": "office-supplies", "type": "clause", "offset": [3076, 3091]}, {"key": "host-party", "type": "definition", "offset": [3099, 3109]}, {"key": "definition-of-a", "type": "clause", "offset": [3252, 3267]}, {"key": "development-of", "type": "clause", "offset": [3495, 3509]}, {"key": "to-ensure", "type": "clause", "offset": [3562, 3571]}, {"key": "hiring-standards", "type": "clause", "offset": [3627, 3643]}, {"key": "comply-with", "type": "clause", "offset": [3700, 3711]}, {"key": "policies-and-procedures", "type": "clause", "offset": [3743, 3766]}, {"key": "with-respect-to", "type": "clause", "offset": [3767, 3782]}, {"key": "site-personnel", "type": "definition", "offset": [3786, 3800]}, {"key": "the-intellectual-property-rights", "type": "clause", "offset": [3882, 3914]}, {"key": "between-the-parties", "type": "clause", "offset": [3915, 3934]}, {"key": "in-this-agreement", "type": "clause", "offset": [3945, 3962]}, {"key": "technical-contacts", "type": "clause", "offset": [4041, 4059]}, {"key": "employees-shall", "type": "clause", "offset": [4190, 4205]}, {"key": "pursuant-to-section", "type": "definition", "offset": [4303, 4322]}, {"key": "to-assist", "type": "clause", "offset": [4487, 4496]}, {"key": "development-obligations", "type": "clause", "offset": [4514, 4537]}, {"key": "mutually-agreed", "type": "clause", "offset": [4549, 4564]}, {"key": "by-the-parties", "type": "clause", "offset": [4582, 4596]}, {"key": "president-level", "type": "clause", "offset": [4611, 4626]}, {"key": "each-party", "type": "clause", "offset": [4631, 4641]}, {"key": "server-software", "type": "definition", "offset": [4839, 4854]}, {"key": "enterprise-edition", "type": "clause", "offset": [5040, 5058]}, {"key": "commercially-reasonable-efforts-to-complete", "type": "clause", "offset": [5095, 5138]}, {"key": "in-time", "type": "definition", "offset": [5171, 5178]}, {"key": "announcement-of-the", "type": "clause", "offset": [5202, 5221]}, {"key": "to-be-completed-by", "type": "definition", "offset": [5394, 5412]}, {"key": "four-months", "type": "definition", "offset": [5516, 5527]}, {"key": "from-time-to-time", "type": "clause", "offset": [5702, 5719]}, {"key": "additional-items", "type": "clause", "offset": [5773, 5789]}, {"key": "the-parties-shall", "type": "clause", "offset": [5907, 5924]}, {"key": "good-faith-negotiations", "type": "definition", "offset": [5935, 5958]}, {"key": "future-release", "type": "definition", "offset": [6016, 6030]}, {"key": "provide-information", "type": "clause", "offset": [6207, 6226]}, {"key": "application-programming-interfaces", "type": "clause", "offset": [6259, 6293]}, {"key": "database-schema", "type": "definition", "offset": [6298, 6313]}, {"key": "in-writing", "type": "clause", "offset": [6436, 6446]}, {"key": "the-requirements", "type": "clause", "offset": [6490, 6506]}, {"key": "notwithstanding-any-provision", "type": "clause", "offset": [6531, 6560]}, {"key": "sole-discretion", "type": "clause", "offset": [6596, 6611]}, {"key": "available-to", "type": "definition", "offset": [6651, 6663]}, {"key": "for-avoidance-of-doubt", "type": "clause", "offset": [6888, 6910]}, {"key": "based-on", "type": "clause", "offset": [6973, 6981]}, {"key": "operating-systems", "type": "clause", "offset": [7039, 7056]}], "size": 1, "hash": "54adfd36c0c33cba610ceeb6e821844e", "id": 8}, {"samples": [{"hash": "8hRlJ7gxZw4", "uri": "/contracts/8hRlJ7gxZw4#development-collaboration", "label": "License and Collaboration Agreement (Sarepta Therapeutics, Inc.)", "score": 27.8501026694, "published": true}], "snippet": "Overview. Prior to the Effective Date, Summit has been engaged in the Development of Licensed Products. Under this Agreement, the Parties will collaborate in the further Development of Licensed Products in accordance with the Development Plan.", "snippet_links": [{"key": "prior-to-the-effective-date", "type": "clause", "offset": [10, 37]}, {"key": "engaged-in", "type": "definition", "offset": [55, 65]}, {"key": "development-of-licensed-products", "type": "clause", "offset": [70, 102]}, {"key": "this-agreement", "type": "clause", "offset": [110, 124]}, {"key": "the-parties-will", "type": "clause", "offset": [126, 142]}, {"key": "further-development", "type": "definition", "offset": [162, 181]}, {"key": "in-accordance-with", "type": "definition", "offset": [203, 221]}, {"key": "the-development-plan", "type": "clause", "offset": [222, 242]}], "size": 1, "hash": "be592ddf731ba908bd9cd5e8d44bfdfa", "id": 9}, {"samples": [{"hash": "8wkFXVcAmCH", "uri": "/contracts/8wkFXVcAmCH#development-collaboration", "label": "Development and Marketing Agreement", "score": 27.052019165, "published": true}], "snippet": "1Overview. Prior to the Effective Date, Alnylam has been engaged in the Development of Licensed Products. Under this Agreement, the Parties will collaborate in the further Development of Licensed Products, with Alnylam retaining all responsibility for the Development of Licensed Products until Phase I Completion as set forth in the Initial Development Plan, and MedCo assuming all other responsibility for the Development of Licensed Products. Initially the Collaboration will include the Development of both ALN-PCS02 and ALN-PSCsc in parallel. In accordance with the process described below, the Parties intend to select one of ALN-PCS02 or ALN-PSCsc for ongoing Development prior to the initiation of IND-enabling studies described in the Initial Development Plan.", "snippet_links": [{"key": "prior-to-the-effective-date", "type": "clause", "offset": [11, 38]}, {"key": "engaged-in", "type": "definition", "offset": [57, 67]}, {"key": "development-of-licensed-products", "type": "clause", "offset": [72, 104]}, {"key": "this-agreement", "type": "clause", "offset": [112, 126]}, {"key": "the-parties-will", "type": "clause", "offset": [128, 144]}, {"key": "further-development", "type": "definition", "offset": [164, 183]}, {"key": "responsibility-for", "type": "clause", "offset": [233, 251]}, {"key": "phase-i-completion", "type": "definition", "offset": [295, 313]}, {"key": "initial-development-plan", "type": "definition", "offset": [334, 358]}, {"key": "other-responsibility", "type": "clause", "offset": [383, 403]}, {"key": "the-collaboration", "type": "clause", "offset": [456, 473]}, {"key": "in-parallel", "type": "definition", "offset": [535, 546]}, {"key": "in-accordance-with", "type": "definition", "offset": [548, 566]}, {"key": "the-process", "type": "clause", "offset": [567, 578]}, {"key": "select-one", "type": "clause", "offset": [618, 628]}, {"key": "ongoing-development", "type": "clause", "offset": [659, 678]}], "size": 1, "hash": "5dba3638a0b0cb494bf527995491e202", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IiJkZXZlbG9wbWVudC1jb2xsYWJvcmF0aW9uIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"title": "Development Collaboration", "parents": [["development", "Development"], ["definitions", "DEFINITIONS"], ["product-development-general", "Product Development General"], ["development-of-product", "Development of Product"], ["discontinuation-of-committees", "Discontinuation of Committees"]], "children": [["overview", "Overview"], ["diligence", "Diligence"], ["third-parties", "Third Parties"], ["development-plans", "Development Plans"], ["pharmacovigilance", "Pharmacovigilance"]], "size": 48, "id": "development-collaboration", "related": [["research-collaboration", "Research Collaboration", "Research Collaboration"], ["development-and-commercialization", "Development and Commercialization", "Development and Commercialization"], ["collaboration-activities", "Collaboration activities", "Collaboration activities"], ["collaboration", "Collaboration", "Collaboration"], ["research-program", "Research Program", "Research Program"]], "related_snippets": [], "updated": "2025-07-07T12:36:13+00:00", "also_ask": [], "drafting_tip": "", "explanation": "The DEVELOPMENT COLLABORATION clause defines the terms under which two or more parties work together on a project or product development. It typically outlines each party\u2019s roles, responsibilities, and contributions, such as sharing resources, intellectual property, or technical expertise. This clause ensures that expectations are clear and that collaboration proceeds smoothly, helping to prevent disputes and misunderstandings during the development process."}, "json": true, "cursor": ""}}